Mapping intermediate degradation products of poly(lactic-co-glycolic acid) in vitro
Jian Li
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Office of Medical Products and Tobacco, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993
Search for more papers by this authorPeter Nemes
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Office of Medical Products and Tobacco, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993
Search for more papers by this authorCorresponding Author
Ji Guo
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Office of Medical Products and Tobacco, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993
Correspondence to: J. Guo; e-mail: [email protected]Search for more papers by this authorJian Li
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Office of Medical Products and Tobacco, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993
Search for more papers by this authorPeter Nemes
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Office of Medical Products and Tobacco, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993
Search for more papers by this authorCorresponding Author
Ji Guo
Division of Biology, Chemistry and Materials Science, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, Office of Medical Products and Tobacco, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993
Correspondence to: J. Guo; e-mail: [email protected]Search for more papers by this authorAbstract
There is widespread interest in using absorbable polymers, such as poly(lactic-co-glycolic acid) (PLGA), as components in the design and manufacture of new-generation drug eluting stents (DES). PLGA undergoes hydrolysis to progressively degrade through intermediate chemical entities to simple organic acids that are ultimately absorbed by the human body. Understanding the composition and structure of these intermediate degradation products is critical not only to elucidate polymer degradation pathways accurately, but also to assess the safety and performance of absorbable cardiovascular implants. However, analytical approaches to determining the intermediate degradation products have yet to be established and evaluated in a standard or regulatory setting. Hence, we developed a methodology using electrospray ionization mass spectrometry to qualitatively and quantitatively describe intermediate degradation products generated in vitro from two PLGA formulations commonly used in DES. Furthermore, we assessed the temporal evolution of these degradation products using time-lapse experiments. Our data demonstrated that PLGA degradation products via heterogeneous cleavage of ester bonds are modulated by multiple intrinsic and environmental factors, including polymer chemical composition, degradants solubility in water, and polymer synthesis process. We anticipate the methodologies and outcomes presented in this work will elevate the mechanistic understanding of comprehensive degradation profiles of absorbable polymeric devices, and facilitate the design and regulation of cardiovascular implants by supporting the assessments of the associated biological response to degradation products. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1129–1137, 2018.
REFERENCES
- 1 Ako J, Bonneau HN, Honda Y, Fitzgerald PJ. Design criteria for the ideal drug-eluting stent. Am J Cardiol 2007; 100: 3M–9M.
- 2 Daemen J, Serruys PW. Drug-eluting stent update 2007: Part I. A survey of current and future generation drug-eluting stents: Meaningful advances or more of the same? Circulation 2007; 116: 316–328.
- 3 Mani G, Feldman MD, Patel D, Agrawal CM. Coronary stents: A materials perspective. Biomaterials 2007; 28: 1689–1710.
- 4 Brown DA, Lee EW, Loh CT, Kee ST. A new wave in treatment of vascular occlusive disease: biodegradable stents–clinical experience and scientific principles. J Vasc Interv Radiol 2009; 20: 315–324.
- 5 Di Mario C, Ferrante G. Biodegradable drug-eluting stents: Promises and pitfalls. Lancet 2008; 371: 873–874.
- 6 Kim S-J, Kim T-H, Choi J-W, Kwon IK. Current perspectives of biodegradable drug-eluting stents for improved safety. Biotechnol Bioprocess Eng 2012; 17: 912–924.
- 7 Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drug-eluting stents. Pharmacol Res 2008; 57: 171–180.
- 8 Ang HY, Bulluck H, Wong P, Venkatraman SS, Huang Y, Foin N. Bioresorbable stents: Current and upcoming bioresorbable technologies. Int J Cardiol 2017; 228: 931–939.
- 9 Foin N, Lee RD, Torii R, Guitierrez-Chico JL, Mattesini A, Nijjer S, Sen S, Petraco R, Davies JE, Di Mario C, et al. Impact of stent strut design in metallic stents and biodegradable scaffolds. Int J Cardiol 2014; 177: 800–808.
- 10 Carlyle WC, McClain JB, Tzafriri AR, Bailey L, Zani BG, Markham PM, Stanley JR, Edelman ER. Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. J Control Release 2012; 162: 561–567.
- 11 Wilson GJ, Marks A, Berg KJ, Eppihimer M, Sushkova N, Hawley SP, Robertson KA, Knapp D, Pennington DE, Chen Y-L, et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study. Catheter Cardiovasc Interv 2015; 86: E247–E257.
- 12 Xi T, Gao R, Xu B, Chen L, Luo T, Liu J, Wei Y, Zhong S. In vitro and in vivo changes to PLGA/sirolimus coating on drug eluting stents. Biomaterials 2010; 31: 5151–5158.
- 13 Lao LL, Venkatraman SS. Paclitaxel release from single and double-layered poly(DL-lactide-co-glycolide)/poly(L-lactide) film for biodegradable coronary stent application. J Biomed Mater Res A 2008; 87: 1–7.
- 14 Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 2011; 3: 1377–1397.
- 15 Kobayashi H, Shiraki K, Ikada Y. Toxicity test of biodegradable polymers by implantation in rabbit cornea. J Biomed Mater Res 1992; 26: 1463–1476.
- 16 Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev 1997; 28: 5–24.
- 17 Ramchandani M, Robinson D. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. 1998; 54: 167–175.
- 18 Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Controlled Release 2001; 70: 1–20.
- 19 Garvin K, Feschuk C. Polylactide-polyglycolide antibiotic implants. Clin Orthop Relat Res 2005; 437: 105–110.
- 20 Grayson AC, Cima MJ, Langer R. Size and temperature effects on poly(lactic-co-glycolic acid) degradation and microreservoir device performance. Biomaterials 2005; 26: 2137–2145.
- 21 Uematsu K, Hattori K, Ishimoto Y, Yamauchi J, Habata T, Takakura Y, Ohgushi H, Fukuchi T, Sato M. Cartilage regeneration using mesenchymal stem cells and a three-dimensional poly-lactic-glycolic acid (PLGA) scaffold. Biomaterials 2005; 26: 4273–4279.
- 22 Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996; 17: 93–102.
- 23 Taylor MS, Daniels AU, Andriano KP, Heller J. Six bioabsorbable polymers: In vitro acute toxicity of accumulated degradation products. J Appl Biomater 1994; 5: 151–157.
- 24 Van Der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690–1697.
- 25 Kenley RA, Lee MO, Mahoney TR, Sanders LM. Poly (lactide-co-glycolide) decomposition kinetics in vivo and in vitro. Macromolecules 1987; 20: 2398–2403.
- 26
Lu L,
Garcia CA,
Mikos AG. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res 1999; 46: 236–244.
10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 27 Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 2000; 21: 1659–1668.
- 28 Grizzi I, Garreau H, Li S, Vert M. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependenceHydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials 1995; 16: 305–311.
- 29 Engineer C, Parikh J, Raval A. Effect of copolymer ratio on hydrolytic degradation of poly(lactide-co-glycolide) from drug eluting coronary stents. Chem Eng Res Des2011; 89: 328–334.
- 30 Ding AG, Schwendeman SP. Determination of water-soluble acid distribution in poly(lactide-co-glycolide). J Pharm Sci 2004; 93: 322–331.
- 31 Hakkarainen M, Adamus G, Höglund A, Kowalczuk M, Albertsson A-C. ESI-MS Reveals the Influence of Hydrophilicity and Architecture on the Water-Soluble Degradation Product Patterns of Biodegradable Homo- and Copolyesters of 1,5-dioxepan-2-one and ε-Caprolactone. Macromolecules 2008; 41: 3547–3554.
- 32 Andersson SR, Hakkarainen M, Inkinen S, Södergård A, Albertsson AC. Polylactide stereocomplexation leads to higher hydrolytic stability but more acidic hydrolysis product pattern. Biomacromolecules 2010; 11: 1067–1073.
- 33 Höglund A, Hakkarainen M, Kowalczuk M, Adamus G, Albertsson A-C. Fingerprinting the degradation product patterns of different polyester-ether networks by electrospray ionization mass spectrometry. J Polym Sci Part A: Polym Chem 2008; 46: 4617–4629.
- 34 Andersson SR, Hakkarainen M, Inkinen S, Södergård A, Albertsson A-C. Customizing the Hydrolytic Degradation Rate of Stereocomplex PLA through Different PDLA Architectures. Biomacromolecules 2012; 13: 1212–1222.
- 35 Belu A, Mahoney C, Wormuth K. Chemical imaging of drug eluting coatings: Combining surface analysis and confocal Raman microscopy. J Controlled Release 2008; 126: 111–121.
- 36 Zamiri P, Kuang Y, Sharma U, Ng TF, Busold RH, Rago AP, Core LA, Palasis M. The biocompatibility of rapidly degrading polymeric stents in porcine carotid arteries. Biomaterials 2010; 31: 7847–7855.
- 37 Dreher ML, Nagaraja S, Li J. Creep loading during degradation attenuates mechanical property loss in PLGA. J Biomed Mater Res Part B: Appl Biomater 2015; 103: 700–708.
- 38 Vey E, Rodger C, Booth J, Claybourn M, Miller AF, Saiani A. Degradation kinetics of poly(lactic-co-glycolic) acid block copolymer cast films in phosphate buffer solution as revealed by infrared and Raman spectroscopies. Polym Degrad Stab 2011; 96: 1882–1889.
- 39 Weir NA, Buchanan FJ, Orr JF, Dickson GR. Degradation of poly-L-lactide. Part 1: in vitro and in vivo physiological temperature degradation. Proc Inst Mech Eng H 2004; 218: 307–319.
- 40 Weir NA, Buchanan FJ, Orr JF, Farrar DF, Dickson GR. Degradation of poly-L-lactide. Part 2: increased temperature accelerated degradation. Proc Inst Mech Eng H 2004; 218: 321–330.
- 41 Li J, Rothstein SN, Little SR, Edenborn HM, Meyer TY. The Effect of Monomer Order on the Hydrolysis of Biodegradable Poly(lactic-co-glycolic acid) Repeating Sequence Copolymers. J Am Chem Soc 2012; 134: 16352–16359.
- 42 Vert M, Li SM, Spenlehauer G, Guerin P. Bioresorbability and biocompatibility of aliphatic polyesters. J Mater Sci Mater Med 1992; 3: 432–446.
- 43 Park TG. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials 1995; 16: 1123–1130.
- 44 Li J, Stayshich RM, Meyer TY. Exploiting Sequence To Control the Hydrolysis Behavior of Biodegradable PLGA Copolymers. J Am Chem Soc 2011; 133: 6910–6913.
- 45 Dreher ML, Nagaraja S, Bui H, Hong D. Characterization of load dependent creep behavior in medically relevant absorbable polymers. J Mech Behav Biomed Mater 2014; 29: 470–479.
- 46 Rosa P. Félix Lanao, Anika M. Jonker, Joop G.C. Wolke, John A. Jansen, Jan C.M. van Hest, Leeuwenburgh SCG. Physicochemical Properties and Applications of Poly(lactic-co-glycolic acid) for Use in Bone Regeneration. >Tissue Eng Part B Rev 2013; 19: 380–390.
- 47 Burkersroda Fv, Schedl L, Göpferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 23: 4221–4231.
- 48 Li J, Washington MA, Bell KL, Weiss RM, Rothstein SN, Little SR, Edenborn HM, Meyer TY. Engineering Hydrolytic Degradation Behavior of Poly(lactic-co-glycolic acid) through Precise Control of Monomer Sequence. Sequence-Controlled Polymers: Synthesis, Self-Assembly, and Properties. American Chemical Society; 2014. p 271–286.
- 49 Auras RA, Lim L-T, Selke SE, Tsuji H. Poly (lactic acid): Synthesis, structures, properties, processing, and applications. John Wiley & Sons; 2011.
- 50 Gentile P, Chiono V, Carmagnola I, Hatton P. An Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering. Int J Mol Sci 2014; 15: 3640–3659.
- 51 Dechy-Cabaret O, Martin-Vaca B, Bourissou D. Controlled Ring-Opening Polymerization of Lactide and Glycolide. Chem Rev 2004; 104: 6147–6176.
- 52 Lasprilla AJR, Martinez GAR, Lunelli BH, Jardini AL, Filho RM. Poly-lactic acid synthesis for application in biomedical devices — A review. Biotechnol Adv 2012; 30: 321–328.
- 53 Rasal RM, Janorkar AV, Hirt DE. Poly(lactic acid) modifications. Prog Polym Sci 2010; 35: 338–356.
- 54 Guo J, Saylor DM, Glaser EP, Patwardhan DV. Impact of artificial plaque composition on drug transport. J Pharm Sci 2013; 102: 1905–1914.